[Anesthetic approach and implications of the use of 5-aminolevulinic acid as a tumor marker in the resection of malignant gliomas].
Fernández-Candil
J
J
Pacreu
S
S
Villaba
G
G
Fernández
Galinski S
GS
D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000528:radiation effects; D000768:Anesthesia, General / Q000379:methods*; D018681:Anesthetics, General / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D000818:Animals; D001932:Brain Neoplasms / Q000737:chemistry / Q000601:surgery*; D003399:Craniotomy; D004347:Drug Interactions; D005456:Fluorescent Dyes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005470:Fluorometry; D005909:Glioblastoma / Q000737:chemistry / Q000601:surgery*; D006801:Humans; D007430:Intraoperative Care; D007431:Intraoperative Complications / Q000139:chemically induced / Q000517:prevention & control; D010777:Photochemistry; D010787:Photosensitivity Disorders / Q000139:chemically induced; D017319:Photosensitizing Agents / Q000009:adverse effects; D017094:Porphyrias, Hepatic / Q000139:chemically induced / Q000517:prevention & control; D011183:Postoperative Complications / Q000139:chemically induced / Q000517:prevention & control; D014466:Ultraviolet Rays
D018681:Anesthetics, General; D005456:Fluorescent Dyes; D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid